4,420 Shares of Becton, Dickinson and Company $BDX Acquired by Capstone Capital Management Ltd

Capstone Capital Management Ltd bought a new position in Becton, Dickinson and Company (NYSE:BDX) in the third quarter, Holdings Channel reports. The institutional investor bought 4,420 shares of the medical instruments supplier’s stock, valued at approximately $791,000.

Several other hedge funds and other institutional investors have also bought and sold shares of BDX. BlackRock Inc. purchased a new position in shares of Becton, Dickinson and Company during the second quarter worth approximately $3,721,533,000. State Street Corp lifted its stake in Becton, Dickinson and Company by 8.5% in the second quarter. State Street Corp now owns 15,000,064 shares of the medical instruments supplier’s stock worth $2,269,960,000 after purchasing an additional 1,177,256 shares during the last quarter. First Eagle Investment Management LLC boosted its position in Becton, Dickinson and Company by 15.8% during the second quarter. First Eagle Investment Management LLC now owns 13,815,335 shares of the medical instruments supplier’s stock valued at $2,090,675,000 after buying an additional 1,887,224 shares during the period. Bank of America Corp DE purchased a new stake in Becton, Dickinson and Company during the second quarter valued at about $474,993,000. Finally, Legal & General Group Plc grew its stake in shares of Becton, Dickinson and Company by 1.5% during the second quarter. Legal & General Group Plc now owns 2,101,695 shares of the medical instruments supplier’s stock valued at $318,050,000 after buying an additional 30,766 shares during the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently commented on the company. TD Cowen lifted their price objective on Becton, Dickinson and Company from $163.00 to $182.00 and gave the stock a “hold” rating in a report on Wednesday, August 5th. UBS Group assumed coverage on Becton, Dickinson and Company in a report on Tuesday, July 28th. They set a “buy” rating and a $190.00 target price for the company. Royal Bank Of Canada lifted their price target on Becton, Dickinson and Company from $180.00 to $190.00 and gave the stock a “sector perform” rating in a research note on Thursday, August 13th. Bank of America boosted their price objective on Becton, Dickinson and Company from $185.00 to $200.00 and gave the company a “neutral” rating in a research report on Monday, August 31st. Finally, Wolfe Research initiated coverage on Becton, Dickinson and Company in a research note on Tuesday. They set an “outperform” rating for the company. Eight analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $185.07.

Becton, Dickinson and Company Price Performance

Shares of Becton, Dickinson and Company stock opened at $193.77 on Wednesday. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55. The company has a market cap of $53.39 billion, a PE ratio of 58.36, a P/E/G ratio of 12.86 and a beta of 0.21. The business has a 50 day moving average of $184.51 and a 200 day moving average of $164.26. Becton, Dickinson and Company has a 52 week low of $127.59 and a 52 week high of $195.99.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, topping analysts’ consensus estimates of $3.14 by $0.09. The company had revenue of $4.98 billion during the quarter, compared to analyst estimates of $4.89 billion. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%. The firm’s revenue was up 5.4% on a year-over-year basis. During the same quarter last year, the firm posted $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, equities research analysts forecast that Becton, Dickinson and Company will post 12.67 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th were given a $1.05 dividend. This represents a $4.20 annualized dividend and a dividend yield of 2.2%. The ex-dividend date of this dividend was Wednesday, September 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 126.51%.

Insider Activity

In related news, CEO Thomas E. Polen, Jr. sold 4,152 shares of the stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $185.00, for a total value of $768,120.00. Following the completion of the transaction, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at $20,380,155. This represents a 3.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total transaction of $440,887.92. Following the completion of the sale, the executive vice president owned 14,856 shares of the company’s stock, valued at $2,686,559.04. This trade represents a 14.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 6,906 shares of company stock valued at $1,265,855. Corporate insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD’s products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.